<DOC>
	<DOCNO>NCT01020604</DOCNO>
	<brief_summary>The report relationship obesity biochemical clinical recurrence prostate cancer controversial . Several report show obesity associate increase risk biochemical clinical failure radical prostatectomy . Other prospective study show adverse effect obesity long-term outcome prostatectomy . Limited report available impact obesity prostate cancer progression radiotherapy . Primary : assess percentage recurrence rate among normal weight overweight obese prostate cancer patient treat adjuvant Zoladex therapy . Secondary : determine Quality Life difference among normal overweight obese prostate cancer patient Quality Life questionnaire</brief_summary>
	<brief_title>PROstaTE Cancer Treatment Obesity Zoladex-Astrazeneca Treated Patients</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<criteria>Histologically proven prostate cancer patient adjuvant Zoladex treatment primary therapy adjuvant therapy without primary curative therapy Prostate cancer patient refractory hormonal therapy , agree participate , allergy treatment</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>BMI</keyword>
	<keyword>Prostate cancer</keyword>
	<keyword>Recurrence</keyword>
</DOC>